Dr. Kate Lynch (nee Williamson)
Kate carried out her medical studies at the University of Adelaide, Australia, completing her MBBS in 2005. She went on to undertake her specialty training in basic physician training and subsequently advanced training in gastroenterology and hepatology through the Royal Australasian College of Physicians, completing her specialisation in 2013.
While performing a one year Senior Clinical Fellowship at the Translational Gastroenterology Unit (TGU) at the John Radcliffe Hospital in Oxford, she became interested in clinical and translational research, particularly in the area of inflammatory bowel disease and autoimmune liver disease, and carried out various clinical audit studies in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). She went on to join Satish Keshav’s laboratory undertaking research into biomarkers in Crohn’s disease, before commencing her DPhil in Clinical Medicine in 2015 with the Nuffield Department of Medicine, under the supervision of Satish Keshav, Paul Klenerman, and Roger Chapman.
She currently holds a Wellcome Trust Clinical Research Fellowship, and is also a sub-investigator on several trials in PBC, PSC, and inflammatory bowel disease. She is a member of the International PSC Study Group, and collaborates on various national and international studies in PSC.
Inflammatory Bowel Disease, Primary Sclerosing Cholangitis, flow cytometry, immunohistochemistry
Dr Kate Williamson - latest publications in PSC: what do they all mean? Dec 2017
Dr Kate Williamson - The PSC Colonoscopy. Oct 2016
- Goode EC, Clark AB, Mells GM… Lynch KD… et al. Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System. Hepatology 2019. doi:doi:10.1002/hep.30479. epub ahead of press.
- Lynch KD, Chapman RW, Keshav S. The use of biologics in patients with inflammatory bowel disease and primary sclerosing cholangitis. Current Hepatology Reports 2019. Accepted, in press.
- Sturrock BRH, Rogers JK, Sadle R, Ferry B, Roberts CA, Chapman RW, Lynch KD. Anti-gp210 and anti-sp100 antibody status and ursodeoxycholic acid response in primary biliary cholangitis.Journal of Gastroenterology and Hepatology Research 2018. 7(6): 2741-47.
- Carbone M, Nardi A, Flack S…. Williamson KD…. et al. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. The Lancet Gastroenterology & Hepatology. 2018;3(9):626-34
- Pheh YS, Harley H, Thompson R, Williamson KD, Bate J, Farah S et al. Biliary transporter gene mutations in severe intrahepatic cholestasis of pregnancy: diagnostic and management implications. Journal of Gastroenterology and Hepatology 2018.doi:10.1111/jgh.14376.
- de Vries EMG*, Wang J*, Williamson KD, Leeflang MMG, Boonstra K,. Weersma RK, Beuers U, Chapman RW, Geskus RB, Ponsioen CY. A novel prognostic model for transplant-free survival in primary sclerosing cholangitis. Gut. 2018;67(10):1864-9.
- De Vries EMG*, de Krijger M*, Farkkila M, Arola J, Schirmacher P, Gotthardt D, Goeppert B, Trivedi PJ, Hirschfield GM, Ytting H, Vainer B, Buuren HR, Biermann K, Harms MH, Chazouillers O, Wendum D, Kemgang AD,Chapman RW, Wang LM1,, Williamson KD, Gouw A, Paradis V, Sempoux C, Beuers U, Hubscher S, Verheij J, Ponsioen C. Validation of the Prognostic Value of Histologic Scoring Systems in Primary Sclerosing Cholangitis; An International Cohort Study. Hepatology, 2017; 65(3):907-19. doi:10.1002/hep.28963.
- Williamson KD, Chapman RW.New Therapeutic Strategies for Primary Sclerosing Cholangitis. Seminars in Liver Disease 2015.36(1):5-14.
- Williamson KD, Chapman RW. Primary Sclerosing Cholangitis: A Clinical Update. British Medical Bulletin 2015; 114:53-64.
- Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, Griffiths L,Lim R, Trembling P, Williamson KD, et al. The UK-PBC Risk Score: derivation and validation of a risk score to predict the need for liver transplantation in patients with PBC. Hepatology 2015. 63 (3): 930-950.